Brazilian Journal of Anesthesiology
https://bjan-sba.org/article/doi/10.1016/j.bjane.2017.10.011
Brazilian Journal of Anesthesiology
Scientific Article

Sugammadex by ideal body weight versus 20% and 40% corrected weight in bariatric surgery - double-blind randomized clinical trial

Uso de sugamadex pelo peso corporal ideal versus corrigido em 20% e 40% em cirurgia bariátrica - ensaio clínico randômico e duplo-cego

Nádia Maria da Conceição Duarte; Ana Maria Menezes Caetano; Silvio da Silva Caldas Neto; Getúlio Rodrigues de Oliveira Filho; Gustavo de Oliveira Arouca; Josemberg Marins Campos

http://dx.doi.org/10.1016/j.bjane.2017.10.011 Braz J Anesthesiol, vol.68, n3, p.219-224, 2018
PDF English
PDF Português
Downloads: 0
Views: 738

Abstract

Abstract Background and objectives: The weight parameters for use of sugammadex in morbidly obese patients still need to be defined. Methods: A prospective clinical trial was conducted with sixty participants with body mass index ≥ 40 kg.m-2 during bariatric surgery, randomized into three groups: ideal weight (IW), 20% corrected body weight (CW20) and 40% corrected body weight (CW40). All patients received total intravenous anesthesia. Rocuronium was administered at dose of 0.6 mg.kg-1 of Ideal weight for tracheal intubation, followed by infusion of 0.3-0.6 mg.kg-1.h-1. Train of four (TOF) was used to monitor depth of blockade. After spontaneous recovery TOF-count 2 at the end of surgery, 2 mg.kg-1 of sugammadex was administered. Primary outcome was neuromuscular blockade reversal time to TOF ≥ 0.9. Secondary outcome was the occurrence of postoperative residual curarization in post-anesthesia recovery room, searching the patient's ability to pass from the surgical bed to the transport, adequacy of oxygenation, respiratory pattern, ability to swallow saliva and clarity of vision. Results: Groups were homogenous in gender, age, total body weight, ideal body weight, body mass index, type and time of surgery. The reversal times (s) were (mean ± standard deviation) 225.2 ± 81.2, 173.9 ± 86.8 and 174.1 ± 74.9 respectively, in the IW, CW20 and CW40 groups (p = 0.087). Conclusions: No differences were observed between groups with neuromuscular blockade reversal time and frequency of postoperative residual curarization. We concluded that ideal body weight can be used to calculate sugammadex dose to reverse moderate neuromuscular blockade in morbidly obese patients.

Keywords

Sugammadex, Bariatric surgery, Body weight, Neuromuscular block, Postoperative residual curarisation

Resumo

Resumo Justificativa e objetivos: Os parâmetros de peso para o uso de sugamadex em pacientes com obesidade mórbida ainda precisam ser definidos. Métodos: Um ensaio clínico prospectivo foi feito com 60 participantes com índice de massa corporal ≥ 40 kg.m-2, submetidos a cirurgia bariátrica, randomizados em três grupos: peso ideal (PI), peso corrigido em 20% (PC20) e peso corrigido em 40% (PC40). Todos os pacientes receberam anestesia intravenosa total. Rocurônio foi administrado em dose de 0,6 mg.kg-1 para intubação traqueal pelo peso ideal, seguido de infusão (0,3 a 0,6 mg.kg-1.h-1). A sequência de quatro estímulos (TOF) foi usada para monitorar a profundidade do bloqueio. Após recuperação espontânea da segunda resposta do TOF no fim da cirurgia, 2 mg.kg-1 de sugamadex foi administrado. O desfecho primário foi o tempo de reversão do bloqueio neuromuscular até obter TOF ≥ 0,9. O desfecho secundário foi a ocorrência de curarização residual pós-operatória na sala de recuperação pós-anestésica, avaliaram-se a capacidade do paciente de passar do leito cirúrgico para o de transporte, a adequação da oxigenação, o padrão respiratório, a habilidade para deglutir saliva e a clareza de visão. Resultados: Os grupos foram homogêneos quanto a gênero, idade, peso corporal total, peso corporal ideal, índice de massa corporal, tipo e tempo de cirurgia. Os tempos de reversão (segundos) foram (média ± desvio-padrão) 225,2 ± 81,2, 173,9 ± 86,8 e 174,1 ± 74,9, respectivamente, nos grupos PI, PC20 e PC40 (p = 0,087). Conclusões: Não foram observadas diferenças entre os grupos quanto ao tempo de reversão do bloqueio neuromuscular e frequência de curarização residual pós-operatória. Concluímos que o peso corporal ideal pode ser usado para calcular a dose de sugamadex para reverter o bloqueio neuromuscular moderado em pacientes com obesidade mórbida.

Palavras-chave

Sugamadex, Cirurgia bariátrica, Peso corporal, Bloqueio neuromuscular, Curarização residual pós-operatória

References

Fried M, Yumuk V, Oppert JM. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24:42-55.

Leykin Y, Miotto L, Pellis T. Pharmacokinetic considerations in the obese. Best Pract Res Clin Anaesthesiol. 2011;25:27-36.

Lemmens HJ. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol. 2010;23:485-91.

Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy. 2012;32:856-68.

Ogunnaike BO, Jones SB, Jones DB. Anesthetic considerations for bariatric surgery. Anesth Analg. 2002;95:1793-805.

Nishiyama T, Kohno Y, Koishi K. Anesthesia for bariatric surgery. Obes Surg. 2012;22:213-9.

Kopman AF, Naguib M. Is deep neuromuscular block beneficial in laparoscopic surgery? No, probably not. Acta Anaesthesiol Scand. 2016;60:717-22.

Mathias LAST, de Bernardis RCG. Postoperative residual paralysis. Braz J Anesthesiol. 2012;62:439-50.

Murphy GS, Szokol JW, Marymont JH. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008;109:389-98.

Locks GF, Cavalcanti IL, Duarte NMC. Use of neuromuscular blockers in Brazil. Braz J Anesthesiol. 2015;65:319-25.

Adam JM, Bennett DJ, Bom A. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002;45:1806-16.

Sacan O, White PF, Tufanogullari B. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569-74.

Sorgenfrei IF, Norrild K, Larsen PB. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667-74.

Mirakhur RK. Sugammadex in clinical practice. Anaesthesia. 2009;64(Suppl. 1):45-54.

Van Lancker P, Dillemans B, Bogaert T. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011;66:721-5.

Llaurado S, Sabate A, Ferreres E. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012;117:93-8.

Carron M, Parotto E, Ori C. The use of sugammadex in obese patients. Can J Anaesth. 2012;59:321-2.

Sanfilippo M, Alessandri F, Wefki Abdelgawwad Shousha AA. Sugammadex and ideal body weight in bariatric surgery. Anesthesiol Res Pract. 2013;2013:389782.

Badaoui R, Cabaret A, Alami Y. Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: in support of dose reduction. Anaesth Crit Care Pain Med. 2016;35:25-9.

Loupec T, Frasca D, Rousseau N. Appropriate dosing of sugammadex to reverse deep rocuronium-induced neuromuscular blockade in morbidly obese patients. Anaesthesia. 2016;71:265-72.

Martini CH, Boon M, Bevers RF. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth. 2014;112:498-505.

Ledowski T. Muscle relaxation in laparoscopic surgery: what is the evidence for improved operating conditions and patient outcome? A brief review of the literature. Surg Laparosc Endosc Percutan Tech. 2015;25:281-5.

Yang L, Wang HL, Zhang LP. Population pharmacokinetics of rocuronium delivered by target-controlled infusion in adult patients. Chin Med J. 2010;123:2543-7.

Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34:1066-9.

Fuchs-Buder T, Claudius C, Skovgaard LT. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789-808.

5dcc35640e88253e17bf58f1 rba Articles
Links & Downloads
2352-2291 (Electronic) 0104-0014 (Printed)
Braz J Anesthesiol ©2024 All rights reserved.

Braz J Anesthesiol

Share this page
Page Sections